surfgreen...I am all for the Canadian uplist! It will bring more liquidity and exposure. IMO ...Who knows maybe company do it after they announce some powerful news about their clinical or patent approval. If not, they probably have some reasons (that we don't know yet) that they prefer not to go that route yet.
I would suspect they will be engaging in a PR/sales company to help with that since the safety study is, or should be complete. Phase 2 efficacy trials should be well advertised by the company to put the share price where it belongs if their product is as good as we think it is. No one within the company is real good at communicating, so hiring someone like this makes sense to me.